InventisBio
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel small molecule drugs for oncology and metabolic diseases, with a leading KRAS G12C inhibitor in global trials.
OncologyMetabolic Diseases
Technology Platform
Proprietary structure-based drug design platform for the discovery and optimization of novel small molecule therapeutics.
Opportunities
Significant market opportunity for its lead KRAS inhibitor if it demonstrates best-in-class profile in ongoing global trials.
Risk Factors
Clinical and regulatory risks associated with its lead asset, alongside potential pricing pressures in the competitive oncology market.
Competitive Landscape
Faces intense competition in the KRAS G12C inhibitor space from large pharma and other biotechs, requiring differentiation in efficacy or safety.